3.52k followers • 20 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
Intuitive Surgical, Inc.
Boston Scientific Corporation
Smith & Nephew plc
Globus Medical, Inc.
Cardiovascular Systems, Inc.
K2M Group Holdings, Inc.
Mazor Robotics Ltd.
With the RBA holdings policy unchanged, the focus returns to the key risk drivers. Continued unrest in the U.S and tensions between the U.S and China are in focus.
The Canadian dollar <CAD=> was trading 1.5% higher at 1.3571 to the U.S. dollar, or 73.69 U.S. cents. "It just seems like everyone wants to sell (U.S.) dollars right now," said Bipan Rai, North America head of FX strategy at CIBC Capital Markets. "The Fed has implemented many measures to make sure that the world is awash in U.S. dollars."
USD/CAD breached the support at 1.3730 and moved closer to 1.3600.
While panic-selling can certainly be unnerving if you're a short-term trader, it's always been an opportunity to buy into great companies at a discount if you're a long-term investor. Throughout the 33-calendar-day decline in the broader market in February and March, I took the opportunity to add quite a few new companies to my investment portfolio. The single greatest thing about Intuitive Surgical is the fact that the company's operating margins are built to improve over time.
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera donor-derived cell-free DNA (dd-cfDNA) transplant rejection assessment test, as well as a multi-site prospective study to externally validate an enhanced algorithm across multiple clinical indications. The PEDAL Study (Prospera Test Enhancement by Detecting Background Cell-Free DNA Levels) will include 500 kidney transplant patients from 20 major U.S. centers.
Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ Mapping System, the DIRECTSENSE Technology, which received U.S. Food and Drug Administration approval in April, is the only tool to monitor changes in local impedance – electrical resistance – around the tip of the INTELLANAV™ MiFi Open-Irrigated (OI) ablation catheter, offering physicians an additional measurement of therapy effect during an ablation.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
DUBLIN, May 29, 2020 -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Jefferies 2020 Global Healthcare.
While the economic calendar is on the busier side, Trump’s news conference will be the main event, which is testing risk sentiment early on.
USD/CAD managed to settle below 1.3800 but received material support at 1.3730.
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Canadian dollar was the only G10 currency to lose ground against the greenback on Thursday as data showed a widening in Canada's current account deficit and ahead of data that was expected to show a slump in Canada's economy. "It has come a long way," said Mark Chandler, head of Canadian fixed income and currency strategy at RBC Capital Markets.
ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the market introduction and first commercial procedure of its Tula System – an in-office solution for placement of tympanostomy tubes (commonly known as ear tubes).
Hologic (NASDAQ: HOLX), after earning an emergency use authorization (EUA) for a second COVID-19 molecular test from the Food and Drug Administration on May 15, is trading just a few dollars off its all-time high of $55.25, set on Feb. 4. The question for the Marlborough, Mass. medical technology company, and for investors, is whether its stock can continue to rise. The company, which has more than 6,000 employees, said it expects to produce an average of 1 million molecular COVID-19 tests per week.